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### Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves: PARTNER 3 Cardiac Computed Tomography Substudy![](fx1_lrg.gif) {#sec1.1.1}

[3003](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)35090-7){#intref0010}

Raj R. Makkar, Philipp Blanke, Jonathon Leipsic, Vinod Thourani, Tarun Chakravarty, David Brown, Alfredo Trento, Robert Guyton, Vasilis Babaliaros, Mathew Williams, Hasan Jilaihawi, Susheel Kodali, Isaac George, Michael Lu, James M. McCabe, John Friedman, Richard Smalling, Shing Chiu Wong, Shahram Yazdani, Deepak L. Bhatt, Jeroen Bax, Samir Kapadia, Howard C. Herrmann, Michael Mack, Martin B. Leon

Subclinical leaflet thrombosis of bioprosthetic aortic valves, characterized by hypoattenuated leaflet thickening and reduced leaflet motion, is present in 1 of 4 patients at 1 year. It is more frequent in transcatheter versus surgical valves at 30 days, but not at 1 year. This is a dynamic finding, with spontaneous resolution in 54% and new appearance in 21% of patients from 30 days to 1 year. The transaortic gradients are increased with increasing severity of this finding and in patients with this finding at both 30 days and 1 year. The impact of this finding on thromboembolic complications and structural valve degeneration needs further assessment.
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### Infective Endocarditis After Transcatheter Aortic Valve Replacement![](fx1_lrg.gif) {#sec1.3.1}
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Infective endocarditis after transcatheter aortic valve replacement (TAVR) occurs at an incidence rate of 1.0 events per 100 person-years, and was associated with a 6.5- and 4.0-fold increased risk of mortality and stroke, respectively. Patients in the peri-procedural period were at highest risk of infective endocarditis (incidence rate of 2.59 events per 100 person-years), and almost every second patient had a pathogen that was not susceptible to the peri-procedural antibiotic prophylaxis. Younger age, male sex, lack of pre-dilatation, and treatment in a catheterization laboratory as opposed to a hybrid operating room were independently associated with endocarditis after TAVR.
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### Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction![](fx1_lrg.gif) {#sec1.5.1}
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The authors examined the clinical course and outcome of end-stage (ES) hypertrophic cardiomyopathy (HCM) patients with systolic dysfunction in the contemporary treatment era. Of 118 ES patients with ejection fraction (EF) \<50%, 48% showed clinical stability in New York Heart Association functional classes I/II over follow-up, while 52% developed refractory disabling heart failure, including 26% requiring heart transplant and 18% experiencing appropriate ICD therapy for potentially lethal ventricular tachyarrhythmias. Current major treatment modalities are associated with reduced ES mortality to 1.9%/year, 4-fold less than previously reported for this HCM complication, with 10-year survival of 85%. Despite improved survival, ES-HCM remains a high-risk clinical feature, with mortality 10-fold that of HCM patients with preserved EF.
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### The Natural History of Severe Calcific Mitral Stenosis![](fx1_lrg.gif) {#sec1.7.1}
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Among 200 patients with isolated severe calcific mitral stenosis (MS) and mitral valve area ≤1.5 cm^2^, 60% were symptomatic at baseline and comorbidities were common (Charlson Comorbidity Index 5.1 ± 1.7). Kaplan-Meier probability of death was 28% at 1 year without intervention. A high burden of comorbidities, but not the presence of symptoms, was associated with all-cause mortality. Transmitral gradient ≥8 mm Hg and right ventricular systolic pressure ≥50 mm Hg were independently associated with all-cause mortality. Among patients with isolated severe calcific MS, these Doppler parameters reflect a critical state of severe calcific MS, but symptomatic status did not.
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### Coronary ^18^F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease![](fx1_lrg.gif) {#sec1.9.1}
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This study assessed whether^18^F-sodium fluoride (^18^F-NaF) positron emission tomography predicts myocardial infarction and provides additional prognostic information to current methods of risk stratification. Patients with known coronary artery disease underwent contrast-enhanced ^18^F-NaF positron emission tomography computed tomography and were followed up for myocardial infarction over 42 months (interquartile range: 31 to 49 months). Among 293 study participants, myocardial infarction occurred only in patients with increased coronary ^18^F-NaF activity. Patients with increased ^18^F-NaF uptake had a \>7-fold increase in myocardial infarction independent of age, sex, cardiovascular risk factors, segment involvement scores, presence of coronary stents, number of vessels with significant stenosis, coronary calcium scoring, Reduction of Atherothrombosis for Continued Health and Secondary Manifestations of Arterial Disease scores, the Duke index, initial patient presentation (acute coronary syndrome or stable), and the study in which individuals were initially recruited.
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### ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak: Endorsed by the American College of Cardiology {#sec2.1.1}
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### Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: *JACC* Review Topic of the Week![](fx1_lrg.gif) {#sec3.1.1}
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is mediated by binding to angiotensin-converting enzyme 2 (ACE2). Because of upregulation of the receptors with angiotensin II receptor blockers, ACE inhibitors, and mineralocorticoid receptor antagonists, it is unclear if clinical management of cardiovascular patients with COVID-19 should be reconsidered. Because the anti-inflammatory benefits of upregulation of the ACE2/Ang1-7/Mas axis in cardiovascular disease and previously demonstrated benefits in improving lung function in SARS-CoV infections, it has been proposed that upregulation of ACE2 expression and/or activity via these cardiac agents could be beneficial in counteracting the systemic dysregulation inflicted by SARS-CoV-2 due to ACE2 dysregulation.
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### Lymphocytic Myocarditis: A Genetically Predisposed Disease? {#sec5.1.1}

[3098](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)35095-6){#intref0075}

Jessica Artico, Marco Merlo, Giulia Delcaro, Antonio Cannatà, Piero Gentile, Giulia De Angelis, Alessia Paldino, Rossana Bussani, Matteo Dal Ferro, Gianfranco Sinagra

### Long-Term Changes in Gut Microbial Metabolite TMAO, CHD Risk, and its Complex Regulatory Network {#sec5.1.2}

[3100](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)35097-X){#intref0080}

Salvatore Patanè

### Trimethylamine N-Oxide and Coronary Heart Disease: Should We Consider the Kidney Function? {#sec5.1.3}
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